- Bioactive Compounds
- By Signaling Pathways
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- Compound Libraries
- Antibodies
- Bioreagents
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- Protein Assay
- Protein A/G Magnetic Beads for IP
- Anti-DYKDDDDK Tag magnetic beads
- Anti-DYKDDDDK Tag Affinity Gel
- Anti-Myc magnetic beads
- Anti-HA magnetic beads
- Poly DYKDDDDK Tag Peptide lyophilized powder
- Protease Inhibitor Cocktail
- Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO)
- Phosphatase Inhibitor Cocktail (2 Tubes, 100X)
- Cell Biology
- Cell Counting Kit-8 (CCK-8)
- Animal Experiment
- Mouse Direct PCR Kit (For Genotyping)
- New Products
- Contact Us
-
Australia
-
Austria
-
Belgium
-
Brazil
-
Canada
-
China
-
Czech Republic
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Hong Kong
-
Hungary
-
Iceland
-
India
-
Ireland
-
Israel
-
Italy
-
Japan
-
Korea
-
Luxembourg
-
Malaysia
-
Netherlands
-
New Zealand
-
Norway
-
Poland
-
Qatar
-
Romania
-
Saudi Arabia
-
Singapore
-
Spain
-
Sweden
-
Switzerland
-
Taiwan
-
Turkey
-
United Kingdom
-
United States
-
Since Jan 2010, Selleck products have been cited in studies from top scientific journals.
16 Nobel Prize winners have published 52 articles with Selleck products.
David Baker
Won the Nobel Prize in Chemistry in 2024
Michael Houghton
Won the Nobel Prize in Physiology or Medicine in 2020
Charles M. Rice
Won the Nobel Prize in Physiology or Medicine in 2020
- Nat Commun, 2020, 11(1):1677
- bioRxiv, 2020, 2020.10.09.334128
- bioRxiv, 2020, 2020.01.20.910927
- Viruses, 2019, 11(11)E1039
- Cell Rep, 2018, 25(4):833-840.e3
- Cell, 2018, 172(3):423-438.e25
- Gastroenterology, 2017, 153(2):566-578.e5
- Gastroenterology, 2016, 150(1):82-85.e4
- Antimicrob, 2016, 60(6):3786-93
- Nature, 2015, 524(7566):471-5
- Antimicrob, 2015, 59(6):3482-92
- J Virol, 2014, 88(20):12098-111
- Antimicrob, 2014, 58(9):5386-94
- J Virol, 2013, 87(13):7593-607
- Nature, 2013, 501(7466):237-41
- Nature, 2013, 99(1):6-11
- Antimicrob, 2012, 56(10):5365-73
William G. Kaelin Jr
Won the Nobel Prize in Physiology or Medicine in 2019
Peter J. Ratcliffe
Won the Nobel Prize in Physiology or Medicine in 2019
Gregg L. Semenza
Won the Nobel Prize in Physiology or Medicine in 2019
Michael Rosbash
Won the Nobel Prize in Physiology or Medicine in 2017
Shinya Yamanaka
Won the Nobel Prize in Physiology or Medicine in 2012
Eric Richard Kandel
Won the Nobel Prize in Physiology or Medicine in 2000
Aziz Sancar
Won the Nobel Prize in Chemistry in 2015
Brian K. Kobilka
Won the Nobel Prize in Chemistry in 2012
Robert Lefkowitz
Won the Nobel Prize in Chemistry in 2012
Featured Products
MRTX1133 is a highly selective inhibitor of mutant KRAS G12D and can reversibly binds to the activated and inactivated KRAS G12D mutants and inhibit their activity. The specificity of MRTX1133 to KRAS G12D is more than 1000 times that of wild-type KRAS.
BI-2865 is a none-covalent pan-KRAS Inhibitor. It binds to WT, G12C, G12D, G12V and G13D mutant KRAS with KDs of 6.9, 4.5, 32, 26, 4.3 nM respectively and inhibits the proliferation of G12C, G12D or G12V mutant KRAS expressing BaF3 ce
AZD0095 is a selective and orally active Monocarboxylate transporter 4 (MCT4) inhibitor with IC50 of 1.3 nM and effectively inhibits the tumor growth in NCI-H358 xenografts in combination with Cediranib.
RMC-7977 is a potent, reversible, tri-complex oral inhibitor that selectively targets active (GTP-bound) forms of KRAS, HRAS, and NRAS, which exhibits broad-spectrum activity against both mutant and wild-type variants (a RASMULTI (ON) inhibitor). It also exhibits significant anti-tumor efficacy in pancreatic ductal adenocarcinoma (PDAC).
HRO761 is a potent, selective, allosteric inhibitor of Werner syndrome RecQ helicase (WRN). It binds at the interface of the D1 and D2 helicase domains, locking WRN in an inactive conformation, and demonstrates anti-proliferative effects specifically in microsatellite instability (MSI) cancer cells.
SB431542 is a potent and selective inhibitor of ALK5 with IC50 of 94 nM in a cell-free assay, 100-fold more selective for ALK5 than p38 MAPK and other kinases.
SB202190 is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis.
LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
MG132 ((S,R,S)-(-)-MG132, Z-Leu-D-Leu-Leu-al) is a potent proteasome (ChTL, TL, and PGPH) inhibitor. MG132 also inhibits calpain (IC50=1.2 μM). MG132 can be used to induce animal models of Parkinson’s disease.
IWP-2 is an inhibitor of Wnt processing and secretion with IC50 of 27 nM in a cell-free assay, selective blockage of Porcn-mediated Wnt palmitoylation, does not affect Wnt/β-catenin in general and displays no effect against Wnt-stimulated cellular responses. IWP-2 specifically inhibits CK1δ.
LDN-193189 (DM3189) 2HCl is a selective BMP signaling inhibitor, inhibits the ALK1, ALK2, ALK3 and ALK6 with IC50s of 0.8 nM, 0.8 nM, 5.3 nM and 16.7 nM in the kinase assay, respectively. LDN-193189 inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50s of 5 nM and 30 nM in C2C12 cells, respectively, exhibits 200-fold selectivity for BMP versus TGF-β.
GW4869 (GW69A, GW554869A) is a neutral, noncompetitive inhibitor of sphingomyelinase (SMase) with an IC50 of 1 μM. It is selective for N-SMase, and does not inhibit acid SMase at up to at least 150 μM, also is a commonly used exosome inhibitor.
A-83-01 is a potent inhibitor of TGF-β type I receptor (ALK5-TD) with IC50 of 12 nM. A-83-01 also inhibits the transcription induced by activin/nodal type I receptor (ALK4-TD) and nodal type I receptor (ALK7-TD) with IC50 of 45 nM and 7.5 nM, respectively.Solutions are unstable and should be fresh-prepared.
GSK484 HCl, a benzoimidazole derivative, is a selective and reversible inhibitor of peptidylarginine deiminase 4 (PAD4) with IC50 of 50 nM in the absence of Calcium.
MCC950 Sodium is a potent, selective inhibitor of NLRP3 with IC50 of 7.5 nM in BMDMs; but not the AIM2, NLRC4 or NLRP1 inflammasomes.
S63845 is a new, selective MCL-1 inhibitor with the Kd value of 0.19 nM and has no discernible binding to the other BCL-2 members, BCL-2 or BCL-XL.
A-485 is a potent, selective and drug-like p300/CBP catalytic inhibitor with an IC50 of 0.06 μM for p300 HAT. It is selective over BET bromodomain proteins and >150 non-epigenetic targets.
AZD7648 is a potent inhibitor of DNA-PK with an IC50 of 0.6 nM in biochemical assay and more than 100-fold selective against 396 other kinases.
PLX5622 is a highly selective CSF-1R inhibitor (IC50 < 10 nmol/L), showing > 20-fold selectivity over KIT and FLT3.
STM2457 is a highly potent and selective first-in-class catalytic inhibitor of RNA Methyltransferase METTL3 with an IC50 of 16.9 nM. STM2457 is highly specific for METTL3 and showed no inhibition of other RNA methyltransferases.
Compound Libraries
A unique collection of 3196 approved drugs and API included in pharmacopoeia for high throughput screening (HTS) and high content screening (HCS).
FDA-approved & Passed Phase I Drug Library
A unique collection of 4213 drugs that are marketed around the world or have passed clinical phase 1 and can be used for high throughput screening (HTS) and high content screening (HCS).
Preclinical/Clinical Compound Library
A unique collection of 3603 preclinical and clinical compounds for high throughput screening (HTS) and high content screening (HCS).
A unique collection of 10526 bioactive compounds for high throughput screening (HTS) and high content screening (HCS).
A unique collection of 5309 bioactive compounds for high throughput screening (HTS) and high content screening (HCS).
A unique collection of 2010 kinase inhibitors for high throughput screening (HTS) and high content screening (HCS).
A unique collection of 3009 chemical compounds featured different core structures and structural diversities respectively for high throughput screening (HTS) and high content screening (HCS).
A unique collection of 3675 natural products for high throughput screening (HTS) and high content screening (HCS).
Human Endogenous Metabolite Compound Library
840 small collections of human endogenous metabolites, involving multiple metabolic pathways, which can be used for high-throughput screening, opening up new ways for humans to treat various diseases such as tumors.
A unique collection of 433 alkaloid compounds used for high throughput screening(HTS) and high content screening(HCS).
New Products
Zotizalkib(TPX-0131) is a compact macrocyclic potent CNS-penetrant, next-generation inhibitor of wild-type ALK and ALK-resistant mutations with an IC50 of 1.4 nM for wild-type ALK. It exhibits antitumor efficacy and can be used in non–small cell lung cancer research.
TYRA-300 , a 3-pyridylindazole analog, is a reversible and selective inhibitor of FGFR3 with an IC50 of 11 nM in Ba/F3 cells. It also exhibit potent activity in human bladder cancer cell lines harboring FGFR3 activating fusions or mutations.
crinecerfont (SSR-125543) is a selective antagonist of the corticotropin-releasing factor type 1 receptor (CRF1R). It lowers elevated adrenal androgens and steroid precursors in adolescents with congenital adrenal hyperplasia (CAH), including those with 21-hydroxylase deficiency.
Nusinersen is an 18-mer, 2′-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide used for treating spinal muscular atrophy (SMA). It binds specifically to the intronic splice silencer N1 (ISS-N1) site in intron 7 of SMN2 pre-mRNA, blocking the binding of splicing repressors hnRNP A1/A2. This promotes inclusion of exon 7 during splicing, restoring full-length SMN protein production in SMA patients.
Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B-100 (apoB-100) that causes selective degradation of apoB-100 mRNA, thereby inhibiting protein translation. This leads to reductions in low-density lipoprotein cholesterol (LDL-C) and other apoB-containing lipoprotein levels. Mipomersen is used as an adjunct treatment for homozygous familial hypercholesterolemia (FH).
Sisunatovir hydrochloride (RV521 hydrochloride) is an orally available and potent inhibitor of the RSV-Fprotein with IC50 values of 1.4 nM and 1.0 nM for RSV A, RSV B, respectively. It effectively reduces RSV viral load and disease severity in humans and has demonstrated a good safety profile in the treatment of an established RSV infection.
Histone H3 (di methyl Lys36) Antibody [H14D5]
Di-Methyl-Histone H3 (Lys36),Histone H3 (di methyl K36)
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.